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Abstract
Lipoxin A4 is a lipid mediator that elicits anti-inﬂammatory and pro-resolution actions via its receptor, formyl peptide receptor 2
(FPR2/ALX). In this study, we aimed to investigate the expression and potential role of lipoxin A4 and FPR2/ALX in the regulation of
inﬂammation associated with cyclical remodeling of the human endometrium across the menstrual cycle and during early pregnancy.
Using quantitative RT-PCR analysis, we found that FPR2/ALX expression is upregulated during the menstrual phase of the cycle and in
decidua tissue from the ﬁrst trimester of pregnancy. We localized the site of expression of FPR2/ALX in menstrual phase endometrium
and ﬁrst-trimester decidua tissue to glandular epithelial cells and cells within the stromal compartment, including cells lining the blood
vessels and immune cells. Measurement of serum lipoxin A4 by ELISA revealed no difference in its levels across the menstrual cycle but an
elevation in early pregnancy (P!0.001). We found that lipoxin A4 was regulated by human chorionic gonadotrophin (hCG) during early
pregnancy, because treatment of human decidua tissue with hCG increased lipoxin A4 release (P!0.01). Finally, we have shown that
lipoxin A4 can suppress phorbol myristate acetate-induced expression of the inﬂammatory cytokines interleukin 6 and 8 in human
endometrium and decidua tissue. These results demonstrate for the ﬁrst time that lipoxin A4 and its receptor FPR2/ALX can regulate
inﬂammatory events in the human endometrium and decidua of early pregnancy.
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Introduction
Inﬂammation occurs during important physiological
events throughout the female reproductive tract, such
as ovulation, menstruation, embryo implantation, and
the initiation of labor (Jabbour et al. 2009). In the
endometrium, inﬂammatory leukocytes are believed to
be important in the tissue breakdown and remodeling
essential for menstruation and the generation of a
receptive endometrium during early pregnancy. Chronic
unregulated inﬂammation in the endometrium has been
linked with several pathologies including heavy men-
strual blood loss (Smith et al. 2007), endometrial cancer
(Wallace et al. 2010), endometriosis (Ryan et al. 1995,
Arici et al. 1997), and recurrent miscarriage (von Wolff
et al. 2000, Laird et al. 2003). Thus, the inﬂammation
associated with menstruation, implantation, and the
establishment of pregnancy must be kept under tight
control in order to ensure reproductive success.
Inﬂammationcanbecontrolledbythelocalproduction
of endogenous anti-inﬂammatory mediators, such as
the steroid hormone cortisol (Chapman et al. 2009), the
cytokine interleukin 10 (IL10; Thaxton & Sharma 2010),
the protein annexin A1 (Perretti & D’Acquisto 2009), and
lipid mediators including the resolvins, protectins, and
lipoxins (Serhan et al. 2008).
The lipoxins (which include the naturally occurring
lipoxin A4 and lipoxin B4, and the aspirin-triggered
lipoxins 15-epimeric lipoxin A4 and 15-epimeric lipoxin
B4) are synthesized from arachidonic acid by the action
of the lipoxygenase enzymes (Chiang et al. 2006).
Lipoxin A4 has been shown to bind to and activate the
G protein-coupled receptor formyl peptide receptor 2
(FPR2/ALX), a member of the FPR family (Ye et al. 2009).
Lipoxin A4 is a dual acting mediator and activates
speciﬁc cellular pathways via FPR2/ALX to elicit both
anti-inﬂammatory and pro-resolution effects (Serhan
et al. 2008).
The lipoxins act as anti-inﬂammatory mediators
by inhibiting neutrophil inﬁltration (Takano et al.
1997, 1998, Hachicha et al. 1999) and transmigration
(Colgan et al. 1993, Kucharzik et al. 2003) at sites
of inﬂammation, in part via the induction of nitric
oxide production to suppress leukocyte–endothelial
interactions (Paul-Clark et al. 2004). Lipoxins can also
inhibit the production of pro-inﬂammatory cytokines
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2007), via the inhibition of transcription factors such as
nuclear factor-kB and activator protein 1 (Gewirtz et al.
2002, Jozsef et al. 2002, Sodin-Semrl et al. 2004, Wu
et al. 2008).
In this study, we aimed to determine the expression
and potential role of lipoxin A4 and FPR2/ALX in
regulating inﬂammation in the human endometrium
and decidua of early pregnancy. We show that FPR2/ALX
is temporally regulated across the menstrual cycle and
during early pregnancy and is expressed in glandular,
vascular, and stromal cells. Furthermore, we show that
serum lipoxin A4 expression is elevated during early
pregnancy and is regulated in ﬁrst-trimester decidua
tissue by human chorionicgonadotrophin (hCG). Finally,
we show that lipoxin A4 acts as an anti-inﬂammatory
mediator in human endometrium and decidua tissue
by counteracting phorbol ester-mediated induction of
pro-inﬂammatory cytokine expression.
Results
Expression and cellular localization of FPR2/ALX
in the human endometrium
The temporal expression pattern of FPR2/ALX mRNA
expression across the menstrual cycle and during early
pregnancy was investigated using quantitative RT-PCR
analysis. Expression of FPR2/ALX (Fig. 1) was signi-
ﬁcantly higher in the menstrual phase of the cycle when
compared with proliferative (P!0.01), early- (P!0.01),
and mid-secretory (P!0.05) phase endometrium. In
ﬁrst-trimester decidua tissue, FPR2/ALX expression was
signiﬁcantly higher than in proliferative (P!0.001),
early- (P!0.001), and mid-secretory (P!0.01) phase
endometrium.
As the mRNA expression of FPR2/ALX was higher in
menstrual phase endometrium and ﬁrst-trimester
decidua, we localized the site of expression of FPR2/ALX
protein in these tissues by immunohistochemistry. In
menstrual phase endometrium (Fig. 2A, B and C), FPR2/
ALX expression was strongest in the functional layer
(Fig. 2A), where it localized to glandular epithelial cells
and distinct cells in the stromal compartment (Fig. 2B)
along with cells lining the blood vessels and immune
cells within the vasculature (Fig. 2C). Similarly, in ﬁrst-
trimester decidua tissue (Fig. 2D and E), FPR2/ALX
expression localized to the glandular epithelium and
decidualized stromal cells (Fig. 2D), cells lining the
blood vessels, and immune cells within the vasculature
(Fig. 2E). Tissue sections incubated with primary
antibody pre-absorbed with an excess of FPR2/ALX
protein were used as a negative control (Fig. 2D; inset).
Serum levels of lipoxin A4 across the menstrual cycle
and during early pregnancy
The endometrial expression pattern of FPR2/ALX
suggested a role for this receptor in regulating inﬂam-
mation associated with menstruation and early preg-
nancy. Therefore, we investigated the levels of its ligand,
lipoxin A4, in the blood of women across the menstrual
cycle and in early pregnancy. There was no signiﬁcant
variation in serum levels of lipoxin A4 across the
menstrual cycle (Fig. 3A). However, serum levels of
lipoxin A4 were signiﬁcantly elevated in samples from
women in the ﬁrst trimester of pregnancy, when
compared with levels in non-pregnant women (Fig. 3B,
P!0.001).
Regulation of lipoxin A4 release by hCG
As we observed an increase in serum levels of lipoxin A4
during early pregnancy, we investigated whether lipoxin
release could beregulated by hCG. Treatment of decidua
tissue explantswith 1 IU hCG for 8 h caused a signiﬁcant
increase in lipoxin A4 release when compared with
vehicle-treated decidua tissue (P!0.01, Fig. 3C).
Lipoxin A4 reduces the expression of inﬂammatory
mediators in human endometrium and decidua tissue
Lipoxin A4 via FPR2/ALX has been shown to mediate
anti-inﬂammatory actions (Bonnans et al. 2007). To
investigate whether lipoxin A4 acts as an anti-inﬂam-
matory mediator in the endometrium, endometrial tissue
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Figure 1 Temporal expression of FPR2/ALX in the human endometrium
and ﬁrst-trimester decidua. mRNA expression levels in human
endometrium across the menstrual cycle (nZ34; consisting of nZ5
menstrual, nZ10 proliferative, nZ7 early secretory, nZ6 mid-
secretory, and nZ6 late secretory phase tissues) and ﬁrst-trimester
decidua tissue (7–12 weeks of gestation; nZ27) are shown for
FPR2/ALX. mRNA levels are expressed relative to a standard
endometrial cDNA sample. Boxes represent data lying within the 5th
to the 95th percentile and whiskers represent the minimum and
maximum values. *, **, and ***Represent signiﬁcance at P!0.05,
P!0.01, and P!0.001, respectively, as determined by ANOVA with
Tukey’s post hoc test.
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phorbol myristate acetate (PMA), either alone or in
combination with lipoxin A4. Treatment with PMA alone
increased the expression of the inﬂammatory cytokines
IL6 (P!0.001, Fig. 4A) and IL8 (P!0.001, Fig. 4B).
Co-treatment of tissues with PMA and lipoxin A4
signiﬁcantly reduced expression of IL6 (P!0.01,
Fig. 4A) and IL8 (P!0.05, Fig. 4B). Similarly, to assess
the anti-inﬂammatory actions of lipoxin A4 during early
pregnancy, decidua tissue was cultured with PMA, alone
or in combination with lipoxin A4. PMA signiﬁcantly
increased the expression of IL6 (P!0.05, Fig. 4C) and
IL8 (P!0.01, Fig. 4D) in decidua tissue explants.
Co-treatment of decidua tissue with PMA and lipoxin
A4 signiﬁcantly suppressed PMA-induced expression of
IL6 and IL8 (P!0.05).
Discussion
Endometrial events, such as menstruation and embryo
implantation, are associated with inﬂammatory pro-
cesses that must be tightly regulated to ensure repro-
ductive success. This is achieved bya delicate balance in
the production of pro- and anti-inﬂammatory mediators
to ensure proper tissue function and homeostasis.
Lipoxin A4 is a recently described anti-inﬂammatory
and pro-resolution lipid mediator, which elicits its
actions via the G protein-coupled receptor FPR2/ALX.
In this study, we investigated the expression and role
of the lipoxin A4-FPR2/ALX system in the human
endometrium.
We found that expression of FPR2/ALX is temporally
regulated across the human menstrual cycle. The
elevation in expression of FPR2/ALX observed in the
endometrium during menstruation suggests a role for
lipoxinA4in regulatingtheinﬂammation associatedwith
endometrial remodeling and repair. Prior to the onset of
menstruation, there is an inﬂux of leukocytes into the
endometrium (Salamonsen & Lathbury 2000), facilitated
by the expression of pro-inﬂammatory chemoattractant
chemokines and cytokines (Arici et al. 1998, Jolicoeur
et al. 1998) and an increase in vascular permeability
(Colditz 1990). These inﬂammatory leukocytes are
thought to contribute to tissue breakdown and vascular
remodeling during menstruation (Zhang et al. 1998,
Sivridis et al. 2001), via the production of pro-
teolytic enzymes such as the matrix metalloproteinases
(Salamonsen & Woolley 1999). Regeneration of the
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Figure 2 Localization of FPR2/ALX protein in
menstrual endometrium and ﬁrst-trimester
decidua. Localization of FPR2/ALX protein in
menstrual endometrium (A, B and C; nZ5) and
during early pregnancy (D and E; nZ5) is shown.
Expression was detected in the glandular
epithelium (g), distinct cells in the stroma (s), and
cells lining the blood vessels (bv) in both tissues.
FPR2/ALX was also detected in immune cells
within the vasculature (C and E). Decidualized
stromal cells showed expression of FPR2/ALX (D).
A representative sample is shown for each tissue.
Negative control (neg) is shown for decidua tissue
(D, insert). Scale barZ100 mm.
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(Ludwig & Spornitz 1991). The mechanisms of endo-
metrial repair have been likened to those of the wound
healing process and involve angiogenesis (Jabbour et al.
2006)andinﬂammatoryprocessessuchastheremovalof
tissue debris by macrophages (Salamonsen & Lathbury
2000). While we observed no signiﬁcant ﬂuctuation in
serum levelsof lipoxin A4 across the menstrual cycle, our
data showing that expression of FPR2/ALX is elevated at
menstruationindicatesapotentialroleforthisreceptorin
regulating the inﬂammatory events involved in endo-
metrial tissue breakdown and regeneration at a local
level. This may be achieved by local production of
lipoxin A4 in the endometrium, or other anti-inﬂam-
matory ligands that can activate FPR2/ALX such as
annexin A1 (Perretti & D’Acquisto 2009).
Lipoxin A4 has previously been demonstrated to
elicit anti-inﬂammatory actions in a variety of cell
types, including epithelial cells (Bonnans et al. 2007),
endothelial cells (Wu et al. 2008), and myometrial
tissue explants (Maldonado-Perez et al. 2011), where it
facilitates tissue remodeling events by reducing the
expression of inﬂammatory chemokines and cytokines.
In order to conﬁrm that lipoxin A4 could regulate
inﬂammatory events in the endometrium, we treated
endometrial tissue with the general inﬂammatory
stimulus PMA. This elevated the expression of the pro-
inﬂammatory cytokines IL6 and IL8. Co-treatment of
endometrial tissue with PMA and lipoxin A4 suppressed
PMA-mediated induction of IL6 and IL8 expression.
These data conﬁrm that lipoxin A4 has the capacity to
mediate anti-inﬂammatory actions in the endometrium.
In addition to its anti-inﬂammatory effects, the lipoxin
A4-FPR2/ALX system can also elicit pro-resolution
actions in order to regulate tissue homeostasis (Serhan
et al. 2008). The resolution of inﬂammation involves the
removal of leukocytes and debris from the site of
inﬂammation and was once thought to be a passive
process caused by the dispersal of chemotatic gradients
(Serhan 2004). However, it is now recognized that the
resolution of inﬂammation is an active process involving
the activation of distinct biochemical pathways that can
be mediated by the lipoxins (Serhan et al. 2008). To
promoteresolution, the lipoxins acceleratethe clearance
of neutrophils from inﬂamed tissues via the promotion of
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Figure 3 Lipoxin A4 serum levels across the menstrual cycle and during
the ﬁrst trimester of pregnancy and regulation of its release by hCG.
LipoxinA4 levelsin serumsamplestakenfroma groupof women onthe
days indicated across the menstrual cycle (A; nZ5 for each day of the
menstrual cycle analyzed). The average level of lipoxin A4 in this group
of non-pregnant women (non-pregnant) was compared with serum
levels measured in a group of women during the ﬁrst trimester of
pregnancy (pregnant; nZ10 from gestational ages 7–12 weeks) (B).
Boxes represent data lying within the 5th to the 95th percentile and
whiskers represent the minimum and maximum values. First-trimester
decidua tissue (nZ6 from gestational ages 7–12 weeks) treated with
1 IU of hCG for 8 h showed a signiﬁcant increase in lipoxin A4 release
into the culture medium, when compared with vehicle-treated control
tissue. Data are meanGS.E.M. ** and ***Represent signiﬁcance at
P!0.01 and P!0.001, respectively, as determined by t test.
3
2
1
Vehicle PMA PMA +
lipoxin A4
Vehicle PMA PMA +
lipoxin A4
Vehicle PMA PMA +
lipoxin A4
Vehicle PMA PMA +
lipoxin A4
0
5 *** *** **
**
*
* * *
4
3
2
1
0
8
6
4
2
0
6
4
2
0
I L 6
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
 
a
b
o
v
e
v
e
h
i
c
l
e
 
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
I L 6
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
 
a
b
o
v
e
v
e
h
i
c
l
e
 
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
I L 8
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
 
a
b
o
v
e
v
e
h
i
c
l
e
 
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
I L 8
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
 
a
b
o
v
e
v
e
h
i
c
l
e
 
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
AB
CD
Figure 4 Anti-inﬂammatory action of lipoxin A4 in endometrium and
deciduatissue.Culturedendometrialtissueconsisting offourindividual
tissues taken across the menstrual cycle (one proliferative, two early
secretory, and one late secretory samples) stimulated with the
inﬂammatory stimulus PMA showed a signiﬁcant increase in the
expression of the inﬂammatory cytokines IL6 (A) and IL8 (B).
The expression of these markers was signiﬁcantly reduced when tissue
was cultured with PMA in combination with lipoxin A4. PMA also
stimulated an increase in the expression of IL6 (C) and IL8 (D) in
cultured decidua tissue (nZ6 from gestational ages 7–12 weeks),
which was signiﬁcantly attenuated by the presence of lipoxin A4.
Data are meanGS.E.M. *, **, and ***Represent signiﬁcance at P!0.05,
P!0.01, and P!0.001, respectively, as determined by t test.
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Reproduction (2011) 142 345–352 www.reproduction-online.orgneutrophil apoptosis (El Kebir et al. 2007), monocyte
migration (Maddox & Serhan 1996), and the non-
phlogistic phagocytosis of apoptotic neutrophils by
monocyte-derived macrophages (Godson et al. 2000).
Our observation that FPR2/ALX is expressed on
glandular epithelial, stromal, vascular, and immune
cells in the endometrium during menstruation suggests
that pro-resolution lipoxin A4-FPR2/ALX signaling may
contribute to controlling the removal of tissue debris
after menstruation. This is essential for wound healing
and tissue regeneration in the endometrium.
Inﬂammatory processes are also important during
early pregnancy, for both the establishment of a
receptive endometrium and in embryo–endometrial
cross talk. Decidualization of the stroma occurs in the
human endometrium in preparation for embryo implan-
tation and trophoblast invasion. As well as differentiation
of the stromal cells, this involves inﬂammatory events
such as inﬁltration of leukocytes, modiﬁcation of the
extra-cellular matrix, and an increase in vascular
permeability (Hess et al. 2007). The developing embryo
also releases many pro-inﬂammatory cytokines, and it
is thought that this induces inﬂammatory pathways in
the endometrium to further enhance its receptivity
(Dimitriadis et al. 2005). Dysregulated inﬂammatory
responses have been associated with recurrent miscar-
riage (von Wolff et al. 2000, Laird et al. 2003); therefore,
these inﬂammatory pathways need to be tightly
regulated to ensure reproductive competence.
We found elevated expression of FPR2/ALX in the
decidua of early pregnancy compared with non-
pregnant endometrium across the menstrual cycle. In
addition, serum lipoxin A4 levels were also signiﬁcantly
increased during the ﬁrst trimester of pregnancy
compared with levels in non-pregnant patients, indicat-
ing potential fetal–maternal cross talk in the regulation of
the inﬂammatory response during early pregnancy. This
led us to investigate the potential of hCG to regulate
lipoxin A4 release. hCG is released from the developing
blastocyst during early pregnancy and maintains pro-
gesterone production from the corpus luteum and
directly regulates gene expression in the endometrium
to facilitate the establishment and maintenance of
pregnancy (Srisuparp et al. 2001, Licht et al. 2007).
We observed an increase in lipoxin A4 release from
cultured decidua tissue treated with hCG. Whether
circulating levels of lipoxin A4 correlate with higher
levels seen at the maternal–fetal interface during
pregnancy is unclear. However, our data strongly suggest
that decidual tissue, in response to embryonic hCG, is
capable of secreting lipoxin A4 which in turn may
contribute to the higher levels seen in early pregnancy.
To conﬁrm that lipoxin A4 could regulate inﬂam-
matory events in the decidua of early pregnancy; we
treated decidua tissue from pregnant women with PMA.
Similar to our observations for treatment of non-pregnant
endometrium, we found that PMA enhanced the
expression of IL6 and IL8 in decidua tissue explants.
This was suppressed by co-treatment of decidua tissue
with PMA and lipoxin A4. Our data showing that lipoxin
A4 can moderate the expression of IL6 and IL8 in the
decidua suggest a mechanism whereby lipoxin A4 may
regulate physiological inﬂammation during early preg-
nancy, by controlling the inﬂammatory processes
required for decidualization and the generation of a
receptive endometrium.
In summary, we demonstrate for the ﬁrst time
expression of the lipoxin A4 receptor FPR2/ALX in the
human endometrium and decidua from the ﬁrst trimester
of pregnancy and show its temporal regulation across
the menstrual cycle. We highlight that lipoxin A4 serum
levels are elevated during early pregnancy and that its
release from the decidua can be regulated by hCG.
Furthermore, we show that lipoxin A4 has an anti-
inﬂammatory action in human endometrium and
decidua tissue. We believe these data demonstrate that
lipoxin A4 signaling via FPR2/ALX represents a novel
mechanism to control the inﬂammation associated with
menstruation and the establishment of pregnancy.
Materials and Methods
Reagents
DMEM/F-12 GlutaMAX culture medium was obtained from
Invitrogen. Lipoxin A4 (used at a ﬁnal concentration of 500 nM)
was purchased from Calbiochem (Nottingham, UK). PMA;
used ata ﬁnal concentration of100 nM andrecombinant (hCG;
used at a ﬁnal concentration of 1 IU) were purchased from
Sigma. FPR2/ALX polyclonal antibody and blocking peptide
were obtained from MBL International (Woburn, MA, USA).
Tissue and serum collection
Endometrial tissue was collected from 34 women aged 21–39
years (consisting of nZ5 menstrual, nZ10 proliferative, nZ7
early secretory, nZ6 mid secretory and nZ6 late secretory
phase tissues) with no underlying endometrial pathology and
regular menstrual cycles (25–35 days) who had not received
any hormonal preparation for 3 months preceding biopsy
collection. The phase of the menstrual cycle for each tissue was
conﬁrmed by histological assessment by a pathologist. Biopsies
were dated according to stated last menstrual period and
conﬁrmed with hormone analysis for circulating estradiol and
progesterone levels; they were consistent with both the stated
last menstrual period and the histological assessment of
the stage of the menstrual cycle. First-trimester decidua tissue
(7–12 weeks gestation; nZ27) was collected from women
undergoing elective surgical termination of pregnancy, with
gestation conﬁrmed by ultra-sound scan. Blood samples were
obtained from two groups of women. The ﬁrst group included
healthy non-pregnant women who attended four visits during a
single menstrual cycle (days 1–3 (menstrual), days 6–8
(follicular), days 13–15 (peri-ovulatory), and days 20–22
(luteal)). The second group included women undergoing
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pregnancy (7–12 weeks gestation). Blood samples were taken
from the antecubital fossa and transported to the laboratory on
ice, where serum was separated by centrifugation and stored at
K20 8C. Ethical approval was obtained from Lothian Ethics
Research Committee, and written informed consent was
obtained before tissue or blood collection.
Tissue culture and treatment
Non-pregnant endometrial tissue and decidua tissue for
explant studies were chopped ﬁnely and maintained in
serum-free DMEM/F-12 medium. For each individual patient
sample, tissue was divided into six roughly equal portions that
were then treated with the three treatments each in duplicate.
Tissue was incubated overnight in serum-free DMEM/F-12
culture medium supplemented with 100 IU penicillin and
100 mg streptomycin, before treatment with 1 IU hCG, 100 nM
PMA, or 100 nM PMAC500 nM lipoxin A4. Tissue explants
were incubated for up to 8 h at 37 8C and 5% CO2 before tissue
was collected for RNA extraction and RT-PCR analysis, or
conditioned medium was collected for ELISA.
Taqman quantitative PCR
Total RNA was extracted from tissue using the RNeasy mini kit
and RNase-free DNase set from Qiagen, according to the
manufacturer’s guidelines. RNA samples were quantiﬁed and
reverse transcribed using the SuperScript VILO cDNA synthesis
kit from Invitrogen. PCR reactions were carried out in duplicate
using an Applied Biosystems ABI 7500 system, UK. Primer and
FAM-labeled probe sequences were as follows (50–30):
FPR2/ALX, forward GCCATCTGCTATGGGCTCAT and reverse
CGTAAGGGACGGCTGGATTT; probe, CAGCCAAGATCCA-
CAAAAAGGGCATG; IL6, forward GCCGCCCCACACAGACA
and reverse CCGTCGAGGATGTACCGAAT; probe, CCA-
CTCACCTCTTCAGAACGAATTCACAAAC; IL8,f o r w a r d
CTGGCCGTGGCTCTCTT and reverse TAGCACTCCTTGG-
CAAAACTG; probe, CCTTCCTGATTTCTGCAGCTCTGTGT-
GAA. The expression of analyzed genes was normalized for
RNA loading using 18S ribosomal RNA primers and probe
(Applied Biosystems, Warrington, UK). Results were calculated
relative to a standard included in all reactions (endometrial
tissue cDNA). Tissue expression levels are shown as relative to
the endometrial tissue cDNA standard, and experimental data
are expressed as fold change compared with control.
Immunohistochemistry
Localization of FPR2/ALX was performed by immunohisto-
chemistry in 5 mm parafﬁn-embedded sections using the Vision
Biosystems Bond Immunostaining Robot under normal operat-
ing conditions (Leica Microsystems, Wetzlar, Germany).
Immunostaining was performed across the menstrual cycle/
decidua on tissue sections from ﬁve different patient samples
per stage of the cycle/decidua following antigen retrieval in
0.01 M sodium citrate buffer (pH 6), using primary antibody
speciﬁc for FPR2/ALX (1:200; 5 mg/ml). Control tissue was
incubated with primary antibody pre-absorbed with a ten times
excess FPR2/ALX protein (50 mg/ml) overnight at 4 8C.
Lipoxin A4 ELISA
Lipoxin A4 levelswere measured in longitudinal serum samples
taken at four points across a single menstrual cycle from the
same group of ﬁve women, a second group of ten patients
during the ﬁrst trimester of pregnancy, and in conditioned
medium from decidua tissue (nZ6 different patients from
gestational ages 7–12 weeks) stimulated with 1 IU hCG, using
an ELISA kit according to the manufacturer’s instructions
(Neogen Corporation, Lexington, KY, USA). Lipoxin A4 was
extracted from serum samples using C18 Sep-Pak columns
(Waters, Elstree, UK) before analysis. Each sample was assayed
in duplicate.
Statistical analysis
Data are shown as meanGS.E.M. and were analyzed by t test or
one-way ANOVAwith Tukey’s post hoc test as described in the
ﬁgure legend (GraphPad Prism, San Diego, CA, USA). All tissue
samples were treated in duplicate at the same time to provide
two pools for each treatment condition. These were then
averaged to a mean value prior to statistical analysis between
and among treatment groups. Statistical analysis was per-
formed on the untransformed data and presented as fold
increase above vehicle control. All samples within an
experiment or set of experiments were subject to the same
pattern of analysis.
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